Enlaza Therapeutics

Covalent Protein Biologics | Home

United States · Founded 2021 · $161.0M raised

Founded
2021
Business Model
B2B
Total Funding
$161.0M
Last Round
$100.0M Series AApr 2024
Rounds
2

About

Enlaza Therapeutics is a preclinical-stage biotech developing first-in-class covalent protein therapeutics, or 'War-Lock' biologics, to treat cancer and other serious diseases. Its proprietary platform incorporates unnatural amino acids into protein drugs to create irreversible, target-specific covalent bonds, aiming to improve efficacy and reduce off-target toxicity compared to standard biologics. The company is backed by investors including J.P. Morgan Life Sciences Private Capital, Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital, and announced a strategic collaboration with Vertex Pharmaceuticals in September 2025.

Summary

Enlaza Therapeutics is a Biotech company based in United States, founded in 2021. It has raised $161.0M in total across 2 rounds, most recently a $100.0M Series A round in Apr 2024. Investors include J.P. Morgan Asset Management, Avalon Ventures and Amgen.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AApr 2024
$100.0M

Sign up to see all 2 rounds

Seed through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Enlaza Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/enlaza-therapeutics"><img src="https://indexed.vc/api/badge/company/enlaza-therapeutics" alt="Enlaza Therapeutics on Indexed.vc" width="260" height="76" /></a>